LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・Exelixis Inc

Exelixis Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

52.52 1.86

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

51.42

Max

52.78

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-34M 210M
Pardavimai	12M 611M
P/E Sektoriaus vid.	16.649 49.888
Pelnas, tenkantis vienai akcijai	0.87
Pelno marža	34.457
Darbuotojai	1,077
EBITDA	15M 258M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	-1.73% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 13B
Ankstesnė atidarymo kaina	50.66
Ankstesnė uždarymo kaina	52.52

Naujienos nuotaikos

By Acuity

50%

154 / 344 reitingas Healthcare

Exelixis Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-03 23:22; UTC

Uždarbis

Pagrindinės rinkos jėgos

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026-06-03 23:09; UTC

Karštos akcijos

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026-06-03 20:51; UTC

Uždarbis

Costco Reports 15% Sales Growth in May

2026-06-03 20:43; UTC

Uždarbis

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026-06-03 23:48; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026-06-03 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-03 23:35; UTC

Rinkos pokalbiai

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026-06-03 23:15; UTC

Rinkos pokalbiai

Uždarbis

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026-06-03 22:08; UTC

Karštos akcijos

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026-06-03 21:54; UTC

Rinkos pokalbiai

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026-06-03 21:18; UTC

Uždarbis

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026-06-03 21:15; UTC

Uždarbis

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026-06-03 21:13; UTC

Uždarbis

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026-06-03 21:13; UTC

Uždarbis

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026-06-03 21:12; UTC

Uždarbis

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026-06-03 21:09; UTC

Uždarbis

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026-06-03 21:03; UTC

Uždarbis

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026-06-03 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-03 20:43; UTC

Uždarbis

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026-06-03 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026-06-03 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026-06-03 20:35; UTC

Uždarbis

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026-06-03 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026-06-03 20:17; UTC

Uždarbis

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026-06-03 20:17; UTC

Uždarbis

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026-06-03 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Adj EPS $2.44 >AVGO

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q EPS $1.91 >AVGO

2026-06-03 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-03 20:15; UTC

Uždarbis

Broadcom 2Q Rev $22.19B >AVGO

Akcijų palyginimas

Kainos pokytis

Exelixis Inc Prognozė

Kainos tikslas

By TipRanks

-1.73% į apačią

12 mėnesių prognozė

Vidutinis 47.7 USD -1.73%

Aukščiausias 56 USD

Žemiausias 40 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Exelixis Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Exelixis Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

154 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.